Comparison of the efficacy of ivermectin cream and ketoconazole cream in treatment of facial seborrheic dermatitis

Comparison of the efficacy of ivermectin 1% cream and ketoconazole 2% cream in treatment of facial seborrheic dermatitis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210222050452N1

Enrollment

Registered

2021-07-15

Start date

2021-05-21

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Facial seborrheic dermatitis. Seborrheic dermatitis, unspecified

Interventions

Intervention 1: Intervention group: Ivermectin 2% cream (Ajanta, Gujrat, India) is applied once overnight and cold cream twice daily on the face. Intervention 2: Control group: Ketoconazole 2% cream

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients more than 18 years old Clinical diagnosis of seborrheic dermatitis (erythematous plaques with greasy and yellowish scales on nose, nasolabial fold, forehead, frown lines, cheek and chin)

Exclusion criteria

Exclusion criteria: ?Severe facial seborrheic dermatitis Using antibiotics or immunomodulatory drugs since one month before beginning of the research Using any topical drugs that can affect seborrheic dermatitis since two weeks before beginning of the study Using any oral drugs that can affect seborrheic dermatitis since one month before beginning of the research Human immunodeficiency virus infection Pregnancy Sensitivity to the research drugs constituents Parkinson'sdisease Lactation

Design outcomes

Primary

Measure	Time frame
Determination of seborrheic dermatitis area and severity index (SEDASI) score. Timepoint: Before intervention and 1 and 2 months after starting intervention. Method of measurement: seborrheic dermatitis area and severity index (SEDASI) score formula.	—

Secondary

Measure	Time frame
Skin erythema index. Timepoint: before intervention and 1 and 2 months after starting intervention. Method of measurement: Dermacatch instrument.;Pruritus severity. Timepoint: before intervention and 1 and 2 months after starting intervention. Method of measurement: ItchyQuant itch illustrated numerical rating scale.;Quality of life. Timepoint: before intervention and 2 months after starting intervention. Method of measurement: Dermatology Life Quality index questionnaire Persian version.	—

Measure

Time frame

Skin erythema index. Timepoint: before intervention and 1 and 2 months after starting intervention. Method of measurement: Dermacatch instrument.;Pruritus severity. Timepoint: before intervention and 1 and 2 months after starting intervention. Method of measurement: ItchyQuant itch illustrated numerical rating scale.;Quality of life. Timepoint: before intervention and 2 months after starting intervention. Method of measurement: Dermatology Life Quality index questionnaire Persian version.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMozhdeh Sepaskhah

Shiraz University of Medical Sciences

sepaskhah@sums.ac.ir+98 71 3484 6316

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026